Propensity score matching analysis: incidence and risk factors for “stardust” gastric mucosa, a novel gastric finding potentially induced by vonoprazan

Vonoprazan, a potassium‐competitive acid blocker, is used for acid‐related diseases. Occasionally, small white protrusions called “stardust” gastric mucosa have been detected in the stomachs of some patients taking vonoprazan.

[1]  Mototsugu Kato,et al.  Vonoprazan-associated Gastric Mucosal Redness: A Report of Four Cases , 2019, Internal medicine.

[2]  Shutian Zhang,et al.  Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis , 2019, Gut.

[3]  Y. Kinoshita,et al.  Relationship of Helicobacter pylori Infection with Gastric Black Spots Shown by Endoscopy , 2018, Internal medicine.

[4]  P. Ungprasert,et al.  Vonoprazan versus proton-pump inhibitors for gastric endoscopic submucosal dissection-induced ulcers: a systematic review and meta-analysis , 2018, European journal of gastroenterology & hepatology.

[5]  N. Uedo,et al.  Efficacy of vonoprazan in prevention of bleeding from endoscopic submucosal dissection-induced gastric ulcers: a prospective randomized phase II study , 2018, Journal of Gastroenterology.

[6]  K. Haruma,et al.  Factors Associated with Gastric Black Spot, White Flat Elevated Mucosa, and Cobblestone-Like Mucosa: A Cross-Sectional Study , 2018, Digestion.

[7]  K. Tominaga,et al.  Does the Novel Potassium-Competitive Acid Blocker Vonoprazan Cause More Hypergastrinemia than Conventional Proton Pump Inhibitors? A Multicenter Prospective Cross-Sectional Study , 2018, Digestion.

[8]  K. Haruma,et al.  Proton Pump Inhibitor Induction of Gastric Cobblestone-like Lesions in the Stomach , 2017, Internal medicine.

[9]  T. Eguchi,et al.  The Effects of Switching to Vonoprazan, a Novel Potassium-Competitive Acid Blocker, on Gastric Acidity and Reflux Patterns in Patients with Erosive Esophagitis Refractory to Proton Pump Inhibitors , 2017, Digestion.

[10]  K. Chayama,et al.  Endoscopic findings of the gastric mucosa during long-term use of proton pump inhibitor – a multicenter study , 2017, Scandinavian journal of gastroenterology.

[11]  T. Eguchi,et al.  A Comparative Study of a New Class of Gastric Acid Suppressant Agent Named Vonoparazan versus Esomeprazole for the Eradication of Helicobacter pylori , 2016, Digestion.

[12]  T. Masaki,et al.  Black Spot, a Novel Gastric Finding Potentially Induced by Proton Pump Inhibitors , 2016, Internal medicine.

[13]  T. Kagawa,et al.  Vonoprazan prevents bleeding from endoscopic submucosal dissection‐induced gastric ulcers , 2016, Alimentary pharmacology & therapeutics.

[14]  Y. Tagawa,et al.  Radiographic Localization Study of a Novel Potassium-Competitive Acid Blocker, Vonoprazan, in the Rat Gastric Mucosa , 2016, Digestive Diseases and Sciences.

[15]  K. Murakami,et al.  Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study , 2016, Gut.

[16]  H. Kurumaya,et al.  White globe appearance is a novel specific endoscopic marker for gastric cancer: A prospective study , 2016, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society.

[17]  N. Hiramatsu,et al.  Randomised clinical trial: vonoprazan, a novel potassium‐competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis , 2015, Alimentary pharmacology & therapeutics.

[18]  K. Yao,et al.  The “white globe appearance” (WGA): a novel marker for a correct diagnosis of early gastric cancer by magnifying endoscopy with narrow-band imaging (M-NBI) , 2015, Endoscopy International Open.

[19]  M. Kajino,et al.  A Study Comparing the Antisecretory Effect of TAK-438, a Novel Potassium-Competitive Acid Blocker, with Lansoprazole in Animals , 2011, Journal of Pharmacology and Experimental Therapeutics.

[20]  M. Kajino,et al.  A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands. , 2011, Biochemical pharmacology.

[21]  P. Austin.  American Journal of Epidemiology Practice of Epidemiology Statistical Criteria for Selecting the Optimal Number of Untreated Subjects Matched to Each Treated Subject When Using Many-to-one Matching on the Propensity Score , 2022 .

[22]  M. Hongo,et al.  Incidence and risk factor of fundic gland polyp and hyperplastic polyp in long-term proton pump inhibitor therapy: a prospective study in Japan , 2010, Journal of Gastroenterology.

[23]  T. Ohkusa,et al.  Effect of CYP2C19 polymorphism on the safety and efficacy of omeprazole in Japanese patients with recurrent reflux oesophagitis , 2005, Alimentary pharmacology & therapeutics.

[24]  J. Sweeney,et al.  Gastric carcinoids in patients with hypergastrinemia. , 2004, Journal of the American College of Surgeons.

[25]  Y. Konda,et al.  Gastrin interferes with the differentiation of gastric pit cells and parietal cells , 2002, Alimentary pharmacology & therapeutics.

[26]  T. Itoh,et al.  Intraglandular necrotic debris in gastric biopsy and surgical specimens. , 2001, Annals of diagnostic pathology.

[27]  T. Takemoto,et al.  An Endoscopic Recognition of the Atrophic Border and its Significance in Chronic Gastritis , 1969 .